577.95
price up icon0.39%   2.26
after-market After Hours: 578.00 0.05 +0.01%
loading
Regeneron Pharmaceuticals Inc stock is traded at $577.95, with a volume of 875.20K. It is up +0.39% in the last 24 hours and up +0.17% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$575.69
Open:
$579.65
24h Volume:
875.20K
Relative Volume:
0.86
Market Cap:
$60.21B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.56
EPS:
39.6877
Net Cash Flow:
$3.56B
1W Performance:
-0.02%
1M Performance:
+0.17%
6M Performance:
-3.64%
1Y Performance:
-37.78%
1-Day Range:
Value
$576.20
$582.70
1-Week Range:
Value
$572.75
$588.71
52-Week Range:
Value
$476.49
$943.83

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,207
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-14-25 Initiated Rothschild & Co Redburn Buy
Jun-30-25 Downgrade Argus Buy → Hold
May-30-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-30-25 Downgrade Wells Fargo Overweight → Equal Weight
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
Oct 24, 2025

Can Regeneron Pharmaceuticals Inc. stock hit record highs againJuly 2025 Trends & Weekly Return Optimization Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

What does recent volatility data suggest for Regeneron Pharmaceuticals Inc.Earnings Risk Report & High Return Stock Watch Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Long Leaf Partners Fund’s Comment on Regeneron (REGN) - Insider Monkey

Oct 24, 2025
pulisher
Oct 24, 2025

What MACD signals say about Regeneron Pharmaceuticals Inc.Quarterly Earnings Summary & Community Consensus Stock Picks - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? - The Globe and Mail

Oct 24, 2025
pulisher
Oct 24, 2025

Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move - BioSpace

Oct 24, 2025
pulisher
Oct 24, 2025

Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent - MSN

Oct 24, 2025
pulisher
Oct 24, 2025

Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Summary & Capital Protection Trading Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsWeekly Profit Summary & AI Powered Trade Plan Recommendations - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged - Reuters

Oct 24, 2025
pulisher
Oct 23, 2025

December 5th Options Now Available For Regeneron Pharmaceuticals (REGN) - Nasdaq

Oct 23, 2025
pulisher
Oct 23, 2025

Canaccord Genuity Maintains Buy Rating on REGN with $850 Target - GuruFocus

Oct 23, 2025
pulisher
Oct 23, 2025

Schaper Benz & Wise Investment Counsel Inc. WI Has $11.74 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 23, 2025
pulisher
Oct 23, 2025

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 23, 2025
pulisher
Oct 23, 2025

Canaccord Genuity Group Reaffirms Buy Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat

Oct 23, 2025
pulisher
Oct 23, 2025

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Increased by Ethic Inc. - MarketBeat

Oct 23, 2025
pulisher
Oct 23, 2025

Cullen Frost Bankers Inc. Sells 445 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 23, 2025
pulisher
Oct 23, 2025

Neutralizing Antibody Market Set for Dynamic Development with - openPR.com

Oct 23, 2025
pulisher
Oct 23, 2025

Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

United States Non-Opioid Pain Treatment Market 2025: Recent - openPR.com

Oct 23, 2025
pulisher
Oct 22, 2025

A Look at Regeneron (REGN) Valuation Following Key Libtayo Approval and Gene Therapy Milestones - simplywall.st

Oct 22, 2025
pulisher
Oct 22, 2025

ARK Investment Management LLC Sells 1,088 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 22, 2025
pulisher
Oct 22, 2025

Private Capital Advisors Inc. Takes $323,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 22, 2025
pulisher
Oct 21, 2025

FDA Expediting Review of Regeneron Drug to Treat Genetic Hearing Loss - The Hearing Review

Oct 21, 2025
pulisher
Oct 21, 2025

Regeneron, Rival End Patent Fight Over Eye Med Biosimilar - Law360

Oct 21, 2025
pulisher
Oct 21, 2025

Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Regeneron Pharmaceuticals (REGN) Joins ClearBridge's Select Stra - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Celltrion Settlement Provides US Date For Aflibercept Entry - Citeline News & Insights

Oct 21, 2025
pulisher
Oct 21, 2025

United States Retinal Biologics: AMD & Diabetic Retinopathy - openPR.com

Oct 21, 2025
pulisher
Oct 21, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DekaBank Deutsche Girozentrale - MarketBeat

Oct 21, 2025
pulisher
Oct 21, 2025

Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Tuesday - MarketBeat

Oct 21, 2025
pulisher
Oct 20, 2025

Is Regeneron Pharmaceuticals Inc. stock resilient to inflationPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Market Activity Recap & Verified Entry Point Signals - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Regeneron and Celltrion Settle Eylea Biosimilar Patent Fight - Bloomberg Law News

Oct 20, 2025
pulisher
Oct 20, 2025

How sentiment analysis helps forecast Regeneron Pharmaceuticals Inc.2025 Winners & Losers & AI Driven Stock Reports - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

New DB-OTO Results Show Sustained Improvements for Children with Profound Genetic Hearing Loss - The Hearing Review

Oct 20, 2025
pulisher
Oct 20, 2025

Will Regeneron Pharmaceuticals Inc. continue its uptrendJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.85 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 20, 2025
pulisher
Oct 20, 2025

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Biotech Giant with 25% Potential Upside - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 20, 2025

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MSN

Oct 20, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$463.43
price down icon 0.12%
$817.32
price up icon 0.63%
biotechnology ONC
$310.81
price up icon 0.25%
$159.66
price down icon 0.29%
$105.66
price up icon 0.87%
Cap:     |  Volume (24h):